Adipocyte and epidermal fatty acid-binding protein serum concentrations in patients with lipodystrophy

作者：Miehle Konstanze^*; Ebert Thomas; Kralisch Susan; Hoffmann Annett; Kratzsch Juergen; Schloegl Haiko; Stumvoll Michael; Fasshauer Mathias

来源：Cytokine, 2017, 92: 20-23.

DOI：10.1016/j.cyto.2017.01.006

• Adipocyte fatty acid-binding protein
• Diabetes mellitus
• Epidermal fatty acid-binding protein
• Insulin resistance
• Lipodystrophy
• Obesity

Objective: Lipodystrophy (LD) syndromes are associated with diabetes mellitus, hypertriglyceridemia, and coronary artery disease. One pathogenetic factor of LD is dysregulation of several adipokines. However, the insulin resistance- and dyslipidemia-promoting adipokines adipocyte (AFABP) and epidermal (EFABP) fatty acid-binding protein have not been investigated in non-HIV-associated LD so far.
Material and methods: We performed a cross-sectional analysis of AFABP and EFABP serum concentrations in 37 LD patients and 37 age-, gender-, and body mass index-matched healthy controls. Moreover, AFABP and EFABP were correlated to clinical and biochemical parameters of inflammation, glucose control, and lipid metabolism.
Results: There was no significant difference in median circulating AFABP and EFABP levels between LD patients (21.7 mil and 7.5 g/l, respectively) and healthy controls (24.5 mil and 8.6 ug/1, respectively). Neither AFABP nor EFABP were related to markers of impaired glucose control or lipid metabolism. Multiple linear regression analysis showed a positive and independent association of AFABP with gender, serum leptin levels, and body mass index.
Conclusions: Circulating levels of AFABP and EFABP are not decreased in LD despite adipose tissue loss in contrast to other adipokines including leptin and adiponectin.

• 出版日期2017-4